Abstract

The programmed cell death ligand 1 (PD-L1) participates in an immune checkpoint system involved in preventing autoimmunity. PD-L1 is expressed on tumor cells, tumor-associated macrophages, and other cells in the tumor microenvironment. Anti–PD-L1 antibodies are active against a variety of cancers, and combined anti–PD-L1 therapy with external beam radiotherapy has been shown to increase therapeutic efficacy. PD-L1 expression status is an important indicator of prognosis and therapy responsiveness, but methods to precisely capture the dynamics of PD-L1 expression in the tumor microenvironment are still limited. In this study, we developed a murine anti–PD-L1 antibody conjugated to the radionuclide Indium-111 (111In) for imaging and biodistribution studies in an immune-intact mouse model of breast cancer. The distribution of 111In-DTPA-anti-PD-L1 in tumors as well as the spleen, liver …

Metadata

publication

Cancer research 76 (2), 472-479, 2016

year

2016

publication date

2016/1/15

authors

Anders Josefsson, Jessie R Nedrow, Sunju Park, Sangeeta Ray Banerjee, Andrew Rittenbach, Fabien Jammes, Benjamin Tsui, George Sgouros

link

https://aacrjournals.org/cancerres/article-abstract/76/2/472/613882

resource_link

https://pmc.ncbi.nlm.nih.gov/articles/PMC4715915/pdf/nihms738054.pdf

journal

Cancer research

volume

76

issue

2

pages

472-479

publisher

American Association for Cancer Research